Analysts Anticipate Aeglea Bio Therapeutics Inc (AGLE) Will Post Earnings of -$0.37 Per Share

Equities analysts predict that Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) will report earnings of ($0.37) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aeglea Bio Therapeutics’ earnings. Aeglea Bio Therapeutics reported earnings per share of ($0.38) during the same quarter last year, which suggests a positive year over year growth rate of 2.6%. The firm is expected to announce its next earnings results on Tuesday, March 12th.

On average, analysts expect that Aeglea Bio Therapeutics will report full-year earnings of ($1.86) per share for the current fiscal year. For the next year, analysts anticipate that the firm will report earnings of ($3.51) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Aeglea Bio Therapeutics.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.10). Aeglea Bio Therapeutics had a negative return on equity of 57.15% and a negative net margin of 480.92%.

A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded Aeglea Bio Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. Wells Fargo & Co downgraded Aeglea Bio Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $22.50.

In other Aeglea Bio Therapeutics news, insider Aaron Schuchart sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, September 27th. The stock was sold at an average price of $9.50, for a total transaction of $57,000.00. Following the transaction, the insider now owns 8,400 shares of the company’s stock, valued at $79,800. The sale was disclosed in a document filed with the SEC, which is available through this link. 18.30% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. Orbimed Advisors LLC boosted its holdings in shares of Aeglea Bio Therapeutics by 26.9% during the second quarter. Orbimed Advisors LLC now owns 1,865,524 shares of the biotechnology company’s stock worth $19,737,000 after acquiring an additional 396,000 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Aeglea Bio Therapeutics by 737.2% during the first quarter. JPMorgan Chase & Co. now owns 50,652 shares of the biotechnology company’s stock worth $502,000 after acquiring an additional 44,602 shares during the period. Deltec Asset Management LLC bought a new stake in shares of Aeglea Bio Therapeutics during the second quarter worth approximately $1,606,000. Dimensional Fund Advisors LP boosted its holdings in shares of Aeglea Bio Therapeutics by 153.9% during the first quarter. Dimensional Fund Advisors LP now owns 91,848 shares of the biotechnology company’s stock worth $911,000 after acquiring an additional 55,679 shares during the period. Finally, Soros Fund Management LLC bought a new stake in shares of Aeglea Bio Therapeutics during the second quarter worth approximately $2,184,000. Institutional investors own 66.23% of the company’s stock.

NASDAQ AGLE traded down $0.42 during trading on Monday, reaching $9.10. 133,051 shares of the company’s stock were exchanged, compared to its average volume of 150,608. The company has a market cap of $200.50 million, a PE ratio of -5.06 and a beta of 0.64. Aeglea Bio Therapeutics has a fifty-two week low of $3.75 and a fifty-two week high of $12.00.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Further Reading: What are the reasons investors use put options?

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit